The SHIELD Study-silicosis
Status
Conditions
Details and patient eligibility
About
An observational cohort study to derive biomarkers which are able to more accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery.
Full description
Background: Silicosis is a fatal lung disease caused by inhaling silica particles. Australia is currently facing an epidemic with hundreds of young workers having contracted silicosis from machining engineered stone. AIMS: To establish the SHIELD COHORT and associated SHIELD BIOBANK to drive further discovery including assessing the efficacy of whole lung lavage for accelerated silicosis, uncovering disease biomarkers, and druggable targets.
PARTICIPANTS: 75 participants who are respirable crystalline silica exposed workers, (this includes n=30 with silicosis, n=15 with progressive massive fibrosis and n=30 with no pneumoconiosis). METHODS: Advanced microscopy, 'omic platforms and single cell RNA sequencing. OUTCOME: The SHIELD study builds on the knowledge gap to accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- All workers with a history of significant engineered stone exposure will be potentially eligible.
Exclusion criteria
Trial contacts and locations
Loading...
Central trial contact
Daniel Chambers; Vidya Navaratnam
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal